Hello, Fool! | Login | Signup | My Fool
Oct 7, 2008 7:31 PM ET | Feedback | Site Changes | Help
The Company and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter.
View All Commentary (FRX)
Recs
biovestor (< 20) Submitted: 6/28/08 3:54 PM : Start Price: $33.38 FRX Score: -5.51
A mid-size specialty pharma company around $10 billion market cap also set to gain from potential approval of milnacipran by end of October 2007 for fibromyalgia (with partner Cypress Bio). Company's products focus mainly on neuro indications such as depression and Alzheimer's with a forward PE below 10.
Report this Post Replies: 0 | Reply
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.